As Director of Operations, Employee Relations and Human Resources, Kevin Kuroda sits toward the top of the scale for Saint Vincent Hospital. But he certainly didn t start out that way. Kuroda sta…
When pandemic hit, some people wanted more sexual activity eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Surgical oncologist at UPMC Hillman Cancer Center and attending surgeon in the Department of Surgery, University of Pittsburgh. view more
Credit: UPMC
PITTSBURGH, April 15, 2021 - Oncologists faced with treating older women with breast cancer often must decide if the treatment may be more detrimental than the cancer. A study published today in
JAMA Network Open by researchers at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine sheds new light on this choice and suggests the rate of cancer recurrence or survival may be no different in treated vs. untreated elderly patients diagnosed in the early stages of the cancer diagnosed most commonly in women.
E-Mail
IMAGE: Cancer evades the immune system by feeding the T cells that protect the tumor and starving the T cells that would attack. view more
Credit: UPMC, created with BioRender.com
PITTSBURGH, Feb. 15, 2021 - A paper published today in
Nature shows how chemicals in the areas surrounding tumors known as the tumor microenvironment subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.
The study was conducted by a team of scientists at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine, led by Greg Delgoffe, Ph.D., Pitt associate professor of immunology. By disrupting the effect of the tumor microenvironment on immune cells in mice, the researchers were able to shrink tumors, prolong survival and increase sensitivity to immunotherapy.
Credit: UPMC
PITTSBURGH, Feb. 4, 2021 - Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy which has a failure rate of 40% for this type of cancer into patients who do.
The results of this proof-of-principle phase II clinical trial were published online today in Science. In this study, a team of researchers from UPMC Hillman administered fecal microbiota transplants (FMT) and anti-PD-1 immunotherapy to melanoma patients who had failed all available therapies, including anti-PD-1, and then tracked clinical and immunological outcomes. Collaborators at NCI analyzed microbiome samples from these patients to understand why FMT seems to boost their response to immunotherapy.